Company intelligence / Profile preview

Regenera Pharma

Ness Ziona, Center District, Israelbloomberg.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Regenera Pharma Ltd. is a private Israeli biotech/pharmaceutical company developing innovative drugs for degenerative nerve diseases, particularly targeting optic nerve neuropathies such as NAION. Its lead candidate RPh201—an extract from mastic gum—was evaluated in Phase 2 trials but the latest study was terminated. The compound aims to restore neural function by stimulating new neuron and synapse formation.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small molecules (notably, triterpenoid extract from mastic gum)
Industry: Biotech

Drug pipeline

1 asset

RPh201

Beyond the preview

Go deeper on Regenera Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regenera Pharma.

Explore the full profile